Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 23, 2021 at 09:16 am
Share
Beijing Hotgen Biotech Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 1,227.559 million compared to CNY 38.371 million a year ago. Operating income was CNY 707.691 million compared to CNY 749,266.95 a year ago. Net income was CNY 601.324 million compared to CNY 512,677.27 a year ago. Basic earnings per share from continuing operations was CNY 9.67 compared to CNY 0.01 a year ago.
Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.
BEIJING HOTGEN BIOTECH CO., LTD. 
